| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6125984 | Transplant Immunology | 2015 | 5 Pages |
Abstract
If eculizumab within the serum did not annihilate rabbit complement activation and basiliximab did not interfere with the crossmatch reaction, treatments based on rituximab, antithymocyte globulin and intravenous immunoglobulins need to be taken into account when interpreting a positive or negative crossmatch test.
Keywords
MoAbsEczABSDTTBSXATGLCTcrossmatchRTXDSAIVIgeculizumabDonor-specific antibodyantibodiesTherapeutic antibodiesHuman leukocyte antigenantithymocyte globulinHLAIntravenous immunoglobulinBasiliximabDrug interferencedithiothreitolRituximabFlow cytometryMonoclonal antibodiesKidney transplantationDesensitization
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
David Milongo, Guillaume Vieu, Sarah Blavy, Arnaud Del Bello, Federico Sallusto, Lionel Rostaing, Nassim Kamar, Nicolas Congy-Jolivet,